{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:15:41Z","timestamp":1789773341229,"version":"4.0.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s11912-019-0804-4","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T05:02:36Z","timestamp":1558674156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Management of Newly Diagnosed Elderly Multiple Myeloma Patients"],"prefix":"10.1007","volume":"21","author":[{"given":"Crystal","family":"Antoine-Pepeljugoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Justin","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"issue":"17","key":"804_CR1","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","volume":"118","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519\u201329.","journal-title":"Blood"},{"issue":"3","key":"804_CR2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"804_CR3","first-page":"212","volume":"110","author":"S Ganguly","year":"2012","unstructured":"Ganguly S. Good health adds life to years. J Indian Med Assoc. 2012;110(4):212\u20133.","journal-title":"J Indian Med Assoc"},{"issue":"2","key":"804_CR4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","volume":"125","author":"PS Rosenberg","year":"2015","unstructured":"Rosenberg PS, Barker KA, Anderson WF. Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity. Blood. 2015;125(2):410\u20132.","journal-title":"Blood"},{"issue":"5","key":"804_CR5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","volume":"29","author":"S Zweegman","year":"2017","unstructured":"Zweegman S, Engelhardt M, Larocca A, EHA SWG on \u2018Aging and Hematology\u2019. Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol. 2017;29(5):315\u201321.","journal-title":"Curr Opin Oncol"},{"issue":"24","key":"804_CR6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/JCO.2014.55.1028","volume":"32","author":"TM Wildes","year":"2014","unstructured":"Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol. 2014;32(24):2531\u201340.","journal-title":"J Clin Oncol"},{"issue":"11","key":"804_CR7","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","volume":"16","author":"D Pulte","year":"2011","unstructured":"Pulte D, Gondos A, Brenner H. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist. 2011;16(11):1600\u20133.","journal-title":"Oncologist"},{"issue":"4","key":"804_CR8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2012.259","volume":"27","author":"SM Bang","year":"2013","unstructured":"Bang SM, Kyle RA, Rajkumar SV, Kumar S. Treatment patterns and outcomes in elderly patients with multiple myeloma. Leukemia. 2013;27(4):971\u20134.","journal-title":"Leukemia"},{"issue":"5","key":"804_CR9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jgo.2016.08.001","volume":"7","author":"N Kint","year":"2016","unstructured":"Kint N, Delforge M. Concise review - treatment of multiple myeloma in the very elderly: how do novel agents fit in? J Geriatr Oncol. 2016;7(5):383\u20139.","journal-title":"J Geriatr Oncol"},{"issue":"10068","key":"804_CR10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"\u2022\u2022 Durie BG, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327 This study established the triplet regmine of bortezomib, lenalidomide, and dexamethasone as superior in patients unfit for ASCT.","journal-title":"Lancet"},{"issue":"6","key":"804_CR11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"\u2022\u2022 Mateos MV, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518\u201328 This was the first study showing the efficacy of mAb therapy in the first line setting and included patients ineligible for ASCT.","journal-title":"N Engl J Med"},{"issue":"6","key":"804_CR12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.seminoncol.2016.10.008","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016;43(6):682\u20139.","journal-title":"Semin Oncol"},{"issue":"10","key":"804_CR13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1634\/theoncologist.2014-0093","volume":"19","author":"ME Hamaker","year":"2014","unstructured":"Hamaker ME, Stauder R, van Munster BC. Exclusion of older patients from ongoing clinical trials for hematological malignancies: an evaluation of the National Institutes of Health Clinical Trial Registry. Oncologist. 2014;19(10):1069\u201375.","journal-title":"Oncologist"},{"issue":"14","key":"804_CR14","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"\u2022\u2022 Attal M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311\u201320 This study brought into consideration the role of ASCT in the era of modern anti-myeloma agents.","journal-title":"N Engl J Med"},{"issue":"9","key":"804_CR15","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/j.clml.2018.06.008","volume":"18","author":"MK Malecek","year":"2018","unstructured":"Malecek MK, Fiala M, Schroeder M, Dukeman J, Ghobadi A, Stockerl-Goldstein K, et al. Multiple myeloma patients ineligible for randomized controlled trials have poorer outcomes irrespective of treatment. Clin Lymphoma Myeloma Leuk. 2018;18(9):e363\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"804_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgo.2016.04.001","volume":"8","author":"TM Wildes","year":"2017","unstructured":"Wildes TM, Campagnaro E. Management of multiple myeloma in older adults: gaining ground with geriatric assessment. J Geriatr Oncol. 2017;8(1):1\u20137.","journal-title":"J Geriatr Oncol"},{"issue":"33","key":"804_CR17","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976\u201384.","journal-title":"J Clin Oncol"},{"issue":"16","key":"804_CR18","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1080\/14656566.2016.1236915","volume":"17","author":"M Gavriatopoulou","year":"2016","unstructured":"Gavriatopoulou M, Terpos E, Kastritis E, Dimopoulos MA. Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother. 2016;17(16):2165\u201377.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"804_CR19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation-2018.1.88","volume":"2018","author":"TM Wildes","year":"2018","unstructured":"Wildes TM, Anderson KC. Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. Hematology Am Soc Hematol Educ Program. 2018;2018(1):88\u201396.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"804_CR20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41375-018-0098-9","volume":"32","author":"H Avet-Loiseau","year":"2018","unstructured":"Avet-Loiseau H, Facon T. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. Leukemia. 2018;32(6):1267\u201376.","journal-title":"Leukemia"},{"issue":"1","key":"804_CR21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0609.2001.00301.x","volume":"66","author":"P Rodon","year":"2001","unstructured":"Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, et al. Multiple myeloma in elderly patients: presenting features and outcome. Eur J Haematol. 2001;66(1):11\u20137.","journal-title":"Eur J Haematol"},{"issue":"6","key":"804_CR22","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1046\/j.1365-2141.2003.04221.x","volume":"120","author":"T Nilsson","year":"2003","unstructured":"Nilsson T, Hoglund M, Lenhoff S, Rylander L, Turesson I, Westin J, et al. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol. 2003;120(6):960\u20139.","journal-title":"Br J Haematol"},{"issue":"22","key":"804_CR23","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","volume":"31","author":"H Avet-Loiseau","year":"2013","unstructured":"Avet-Loiseau H, Hulin C, Campion L, Rodon P, Marit G, Attal M, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myelome experience. J Clin Oncol. 2013;31(22):2806\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"804_CR24","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","volume":"117","author":"F Gay","year":"2011","unstructured":"Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025\u201331.","journal-title":"Blood"},{"issue":"13","key":"804_CR25","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood-2009-10-163329","volume":"116","author":"J Mehta","year":"2010","unstructured":"Mehta J, Cavo M, Singhal S. How I treat elderly patients with myeloma. Blood. 2010;116(13):2215\u201323.","journal-title":"Blood"},{"issue":"6","key":"804_CR26","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","volume":"98","author":"S Bringhen","year":"2013","unstructured":"Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6):980\u20137.","journal-title":"Haematologica"},{"issue":"9868","key":"804_CR27","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381","author":"A Clegg","year":"2013","unstructured":"Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752\u201362.","journal-title":"Lancet"},{"issue":"19","key":"804_CR28","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","volume":"126","author":"A Larocca","year":"2015","unstructured":"Larocca A, Palumbo A. How I treat fragile myeloma patients. Blood. 2015;126(19):2179\u201385.","journal-title":"Blood"},{"issue":"5","key":"804_CR29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2017-09-746420","volume":"131","author":"GA Abel","year":"2018","unstructured":"Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018;131(5):515\u201324.","journal-title":"Blood"},{"key":"804_CR30","doi-asserted-by":"crossref","unstructured":"Mian HS, Wildes TM, Fiala MA. Development of a Medicare Health Outcomes Survey deficit-accumulation frailty index and its application to older patients with newly diagnosed multiple myeloma. JCO Clin Cancer Inform. 2018;2.","DOI":"10.1200\/CCI.18.00043"},{"key":"804_CR31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/EdBook_AM.2013.33.208","volume":"33","author":"HD Klepin","year":"2013","unstructured":"Klepin HD, Rizzieri D, Palumbo A, Magarotto V, Eichhorst B. Individualizing treatment decisions for older adults with hematologic malignancies. Am Soc Clin Oncol Educ Book. 2013;33:208\u201319.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"13","key":"804_CR32","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"\u2022\u2022 Palumbo A, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068\u201374 This paper established the IMWG geriatric assessment for determining frailty in elderly MM patients.","journal-title":"Blood"},{"key":"804_CR33","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","volume":"185","author":"S Katz","year":"1963","unstructured":"Katz S, et al. Studies of illness in the aged. The index of Adl: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914\u20139.","journal-title":"JAMA"},{"issue":"3","key":"804_CR34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179\u201386.","journal-title":"Gerontologist"},{"issue":"5","key":"804_CR35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"9","key":"804_CR36","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.34","volume":"1","author":"M Kleber","year":"2011","unstructured":"Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, W\u00e4sch R, et al. Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J. 2011;1(9):e35.","journal-title":"Blood Cancer J"},{"issue":"5","key":"804_CR37","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"\u2022\u2022 Engelhardt M, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910\u201321 This study presented with R-MCI for incorporating cytogenetics into a geriatric assessment score to assess elderly MM patients.","journal-title":"Haematologica"},{"issue":"9","key":"804_CR38","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","volume":"101","author":"M Engelhardt","year":"2016","unstructured":"\u2022 Engelhardt M, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101(9):1110\u20139 The study validated the IMWG frailty score.","journal-title":"Haematologica"},{"issue":"11","key":"804_CR39","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","volume":"91","author":"P Milani","year":"2016","unstructured":"\u2022 Milani P, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016;91(11):1129\u201334 A simple frailty score was presented in this paper.","journal-title":"Am J Hematol"},{"issue":"11","key":"804_CR40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11912-017-0631-4","volume":"19","author":"A Baronner","year":"2017","unstructured":"Baronner A, MacKenzie A. Using geriatric assessment strategies to lead end-of-life care discussions. Curr Oncol Rep. 2017;19(11):75.","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"804_CR41","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114(3):600\u20137.","journal-title":"Br J Haematol"},{"key":"804_CR42","unstructured":"https:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-decision-memo.aspx?NCAId=10&bc=ACAAAAAAQAAA&\n                      \n                    . Centers for Medicare and Medicaid Services."},{"issue":"10","key":"804_CR43","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.bbmt.2015.05.013","volume":"21","author":"GL Shah","year":"2015","unstructured":"Shah GL, Winn AN, Lin PJ, Klein A, Sprague KA, Smith HP, et al. Cost-effectiveness of autologous hematopoietic stem cell transplantation for elderly patients with multiple myeloma using the surveillance, epidemiology, and end results-Medicare database. Biol Blood Marrow Transplant. 2015;21(10):1823\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"804_CR44","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122\u20138.","journal-title":"Leukemia"},{"issue":"8","key":"804_CR45","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/bmt.2015.106","volume":"50","author":"TM Wildes","year":"2015","unstructured":"Wildes TM, Finney JD, Fiala M, Gao F, Vij R, Stockerl-Goldstein K, et al. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Bone Marrow Transplant. 2015;50(8):1075\u201382.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"804_CR46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13608","volume":"171","author":"HW Auner","year":"2015","unstructured":"Auner HW, Garderet L, Kroger N. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. Br J Haematol. 2015;171(4):453\u201362.","journal-title":"Br J Haematol"},{"issue":"11","key":"804_CR47","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3324\/haematol.2016.150334","volume":"101","author":"L Garderet","year":"2016","unstructured":"\u2022 Garderet L, et al. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Haematologica. 2016;101(11):1390\u20137 Investigators presented prospective safety and efficacy data for ASCT in elderly patients.","journal-title":"Haematologica"},{"issue":"4","key":"804_CR48","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.V94.4.1248","volume":"94","author":"A Palumbo","year":"1999","unstructured":"Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood. 1999;94(4):1248\u201353.","journal-title":"Blood"},{"issue":"10","key":"804_CR49","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","volume":"104","author":"A Palumbo","year":"2004","unstructured":"Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104(10):3052\u20137.","journal-title":"Blood"},{"issue":"10","key":"804_CR50","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354(10):1021\u201330.","journal-title":"N Engl J Med"},{"issue":"9594","key":"804_CR51","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","volume":"370","author":"T Facon","year":"2007","unstructured":"Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209\u201318.","journal-title":"Lancet"},{"issue":"1","key":"804_CR52","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","volume":"2017","author":"MV Mateos","year":"2017","unstructured":"Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematology Am Soc Hematol Educ Program. 2017;2017(1):498\u2013507.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"804_CR53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/10428194.2016.1177772","volume":"58","author":"K Weisel","year":"2017","unstructured":"Weisel K, Doyen C, Dimopoulos M, Yee A, Lahuerta JJ, Martin A, et al. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leuk Lymphoma. 2017;58(1):153\u201361.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"804_CR54","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2013-02-483073","volume":"122","author":"F Gay","year":"2013","unstructured":"Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood. 2013;122(8):1376\u201383.","journal-title":"Blood"},{"issue":"11","key":"804_CR55","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3324\/haematol.2016.151860","volume":"101","author":"C Straka","year":"2016","unstructured":"Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, et al. Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. Haematologica. 2016;101(11):1398\u2013406.","journal-title":"Haematologica"},{"issue":"8","key":"804_CR56","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912\u20139.","journal-title":"Blood"},{"issue":"3","key":"804_CR57","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bbmt.2013.12.557","volume":"20","author":"A Saad","year":"2014","unstructured":"Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20(3):402\u20138 e1.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"804_CR58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1053\/j.seminoncol.2016.11.006","volume":"43","author":"M Braunstein","year":"2016","unstructured":"Braunstein M, Niesvizky R. Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma. Semin Oncol. 2016;43(6):709\u201311.","journal-title":"Semin Oncol"},{"key":"804_CR59","doi-asserted-by":"crossref","unstructured":"Elsayed, H.G. and A.S. Alabdulwahab, Upfront treatment of elderly myeloma patients: an overview and update. Expert Rev Hematol, 2017.","DOI":"10.1080\/17474086.2018.1419861"},{"issue":"7","key":"804_CR60","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719\u201334.","journal-title":"Am J Hematol"},{"issue":"24","key":"804_CR61","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955\u201362.","journal-title":"Blood"},{"key":"804_CR62","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/EDBK_200879","volume":"38","author":"A Perrot","year":"2018","unstructured":"Perrot A, Corre J, Avet-Loiseau H. Risk stratification and targets in multiple myeloma: from genomics to the bedside. Am Soc Clin Oncol Educ Book. 2018;38:675\u201380.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"19","key":"804_CR63","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375\u201382.","journal-title":"Blood"},{"issue":"9","key":"804_CR64","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906\u201317.","journal-title":"N Engl J Med"},{"issue":"19","key":"804_CR65","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759\u201369.","journal-title":"N Engl J Med"},{"issue":"10","key":"804_CR66","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906\u201317.","journal-title":"N Engl J Med"},{"issue":"33","key":"804_CR67","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","volume":"33","author":"R Niesvizky","year":"2015","unstructured":"Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, et al. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015;33(33):3921\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"804_CR68","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","volume":"118","author":"PM Fayers","year":"2011","unstructured":"Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksa\u00e7 M, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239\u201347.","journal-title":"Blood"},{"issue":"30","key":"804_CR69","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","volume":"34","author":"C Hulin","year":"2016","unstructured":"\u2022 Hulin C, et al. Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. J Clin Oncol. 2016;34(30):3609\u201317 A pivotal study that eatablished the role of Rd in prolonging OS of elderly MM patients.","journal-title":"J Clin Oncol"},{"issue":"9","key":"804_CR70","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","volume":"127","author":"V Magarotto","year":"2016","unstructured":"Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102\u20138.","journal-title":"Blood"},{"issue":"2","key":"804_CR71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O'Donnell","year":"2018","unstructured":"\u2022 O'Donnell EK, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222\u201330 In this study, investigators demonstrate the safety of a dose-attenuate modern triple regimen (RVD-lite) in MM patients not fit for ASCT.","journal-title":"Br J Haematol"},{"issue":"3","key":"804_CR72","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2015.223","volume":"30","author":"S Lonial","year":"2016","unstructured":"Lonial S, Durie B, Palumbo A, San-Miguel J. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30(3):526\u201335.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"804_CR73","doi-asserted-by":"crossref","first-page":"LBA-2","DOI":"10.1182\/blood-2018-120737","volume":"132","author":"T Facon","year":"2018","unstructured":"Facon T, et al. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA). Blood. 2018;132(Suppl 1):LBA-2.","journal-title":"Blood"},{"issue":"3","key":"804_CR74","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","volume":"20","author":"LJ Melton 3rd","year":"2005","unstructured":"Melton LJ 3rd, et al. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20(3):487\u201393.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"804_CR75","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"\u2022 Raje N, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370\u201381 This study established non-inferiority between bisphosphonates and RANK-L inhibitor denosumab in preventing skeletal-related events in MM.","journal-title":"Lancet Oncol"},{"issue":"18","key":"804_CR76","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","volume":"31","author":"E Terpos","year":"2013","unstructured":"Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, et al. International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347\u201357.","journal-title":"J Clin Oncol"},{"issue":"1","key":"804_CR77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3857\/roj.2016.34.1.59","volume":"34","author":"JW Lee","year":"2016","unstructured":"Lee JW, Lee JE. Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions. Radiat Oncol J. 2016;34(1):59\u201363.","journal-title":"Radiat Oncol J"},{"issue":"8","key":"804_CR78","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735\u201344.","journal-title":"Cancer"},{"issue":"21","key":"804_CR79","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","volume":"19","author":"GJ Morgan","year":"2013","unstructured":"Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, et al. Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013;19(21):6030\u20138.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"804_CR80","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","volume":"36","author":"K Anderson","year":"2018","unstructured":"Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(8):812\u20138.","journal-title":"J Clin Oncol"},{"issue":"35","key":"804_CR81","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1200\/JCO.2017.73.7437","volume":"35","author":"CL Shapiro","year":"2017","unstructured":"\u2022 Shapiro CL, et al. Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance). J Clin Oncol. 2017;35(35):3949\u201355 This study established non-inferiority of every 3 month dosing of zoledronic acid in patients with skeletal metastasis.","journal-title":"J Clin Oncol"},{"issue":"8","key":"804_CR82","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/1078-0432.CCR-11-0498","volume":"18","author":"AA Chanan-Khan","year":"2012","unstructured":"Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, Dimopoulos MA. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Clin Cancer Res. 2012;18(8):2145\u201363.","journal-title":"Clin Cancer Res"},{"key":"804_CR83","unstructured":"https:\/\/www.cdc.gov\/oralhealth\/publications\/factsheets\/adult_oral_health\/adult_older.htm\n                      \n                    . Centers for Disease Control and Prevention."},{"key":"804_CR84","doi-asserted-by":"crossref","unstructured":"Paner, A., et al., Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities. Expert Rev Hematol, 2018.","DOI":"10.1080\/17474086.2018.1538777"},{"issue":"23","key":"804_CR85","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","volume":"127","author":"PA Carpenter","year":"2016","unstructured":"Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016;127(23):2824\u201332.","journal-title":"Blood"},{"issue":"7","key":"804_CR86","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","volume":"32","author":"H Ludwig","year":"2018","unstructured":"Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018;32(7):1542\u201360.","journal-title":"Leukemia"},{"issue":"12","key":"804_CR87","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1634\/theoncologist.2012-0192","volume":"17","author":"D Hui","year":"2012","unstructured":"Hui D, Kim SH, Kwon JH, Tanco KC, Zhang T, Kang JH, et al. Access to palliative care among patients treated at a comprehensive cancer center. Oncologist. 2012;17(12):1574\u201380.","journal-title":"Oncologist"},{"issue":"13","key":"804_CR88","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1200\/JCO.2014.58.6362","volume":"33","author":"MA Bakitas","year":"2015","unstructured":"Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z, et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol. 2015;33(13):1438\u201345.","journal-title":"J Clin Oncol"},{"issue":"3","key":"804_CR89","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/17474086.2015.1021772","volume":"8","author":"H Maes","year":"2015","unstructured":"Maes H, Delforge M. Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations. Expert Rev Hematol. 2015;8(3):355\u201366.","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"804_CR90","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29119","volume":"121","author":"EE Kent","year":"2015","unstructured":"Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD. Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer. 2015;121(5):758\u201365.","journal-title":"Cancer"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0804-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-019-0804-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0804-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T23:21:08Z","timestamp":1590189668000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-019-0804-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":90,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s11912-019-0804-4","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]},"assertion":[{"value":"24 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Crystal Antoine-Pepeljugoski declares that she has no conflicts of interest.Marc Justin Braunstein has received consulting fees from Celgene, Janssen, AstraZeneca, Amgen, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"64"}}